Delcath Q4 revenue rises 37%, beats estimates

Delcath Systems

26/02/2026 13:09

Overview

Interventional oncology firm's Q4 revenue rose, beating analyst expectations

Company reported Q4 net loss but achieved positive adjusted EBITDA

Company repurchased 628,572 shares for $6 mln under buyback program

Outlook

Company expects 2026 revenue of at least $100 mln, driven by HEPZATO KIT volume growth

Delcath anticipates gross margins between 84% and 87% for fiscal year 2026

Company aims for accelerated adoption through site activations and commercial expansion

Result Drivers

HEPZATO GROWTH - 140% increase in HEPZATO procedure volume compared to 2024 drove revenue growth

CLINICAL TRIAL RESULTS - Positive results from CHOPIN trial and other studies increased awareness and demand

EXPANDED CAPACITY - 28 active centers contributed to increased procedure volume and revenue

Company press release: ID:nBw5M0s78a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$20.73 mln
$20.33 mln (7 Analysts)
Q4 EPS
-$0.05
Q4 Net Income
-$1.90 mln
Q4 Gross Profit
$17.72 mln
Q4 Operating Expenses
$19.90 mln
Q4 Operating Income
-$2.18 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Delcath Systems Inc is $22.00, about 115.5% above its February 25 closing price of $10.21

The stock recently traded at 41 times the next 12-month earnings vs. a P/E of 26 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)